Good manufacturing practice requirements for the production of tissue vitrification and warming and recovery kits for clinical research
- 411 Downloads
Products that are manufactured for use in a clinical trial, with the intent of gaining US Food and Drug Administration (FDA) approval for clinical use, must be produced under an FDA approved investigational new drug (IND) application. We describe work done toward generating reliable methodology and materials for preserving ovarian cortical tissue through a vitrification kit and reviving this tissue through a warming and recovery kit. We have described the critical steps, procedures, and environments for manufacturing products with the intent of submitting an IND. The main objective was to establish an easy-to-use kit that would ensure standardized procedures for quality tissue preservation and recovery across the 117 Oncofertility Consortium sites around the globe. These kits were developed by breaking down the components and steps of a research protocol and recombining them in a way that considers component stability and use in a clinical setting. The kits were manufactured utilizing current good manufacturing practice (cGMP) requirements and environment, along with current good laboratory practices (cGLP) techniques. Components of the kit were tested for sterility and endotoxicity, and morphological endpoint release criteria were established. We worked with the intended down-stream users of these kits for development of the kit instructions. Our intention is to test these initial kits, developed and manufactured here, for submission of an IND and to begin clinical testing for preserving the ovarian tissue that may be used for future restoration of fertility and/or hormone function in women who have gonadal dysgenesis from gonadotoxic treatment regimens or disease.
KeywordsGood manufacturing practice Vitrification Ovary Oncofertility
This work is supported by the Watkins Chair of Obstetrics and Gynecology (TKW), the UH3TR001207 (NCATS, NICHD, NIEHS, OWHR, NIH Common Fund), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development U54HD076188 grant. The Oncofertility Consortium ® is funded by the National Institutes of Health through the NIH Roadmap for Medical Research, Grant UL1DE19587 and PL1CA133835, and the Center for Reproductive Health After Disease P50HD076188 grant from the National Institutes of Health National Center for Translational Research in Reproduction and Infertility (NCTRI). MML acknowledges support from The Burroughs Wellcome Fund Career Award at the Scientific Interface and the John and Lillian Mathews Regenerative Medicine Endowment. This work was supported by the Northwestern University Mouse Histology and Phenotyping Laboratory and a Cancer Center Support Grant (NCI CA060553). The authors thank Greg Fahy, from 21st Century Medicine, for gifting the Super Cool polymers used in this study; Clarisa Gracia and Jessica Brown, from the University of Pennsylvania, for giving us feedback on the operational procedures as performed in a fertility clinic; Cheryl Hanson, from the Mathews Center, for Good Manufacturing Practice training and feedback on procedures; and Steven Mullen, from Cook Regentec, for his role in developing the initial vitrification media recipes. We also thank Keisha Barreto from the Ovarian Histology Core at Northwestern University for her technical expertise.
Standard Operating Procedure for Preparing Ovarian Tissue for Vitrification Using the Stadie-Riggs Tissue Slicer. Fresh bovine ovaries were prepared using the Stadie-Riggs tissue slicer to achieve 0.5 mm thick pieces of cortex. (MOV 292 mb)
- 1.Food and Drug Administration. Current Good Manufacturing Practice in Manufacturing Processing, packing, or Holding of Drugs. [Internet]. 21; Apr 6, 2016. Available from: http://www.ecfr.gov/cgi-bin/text-idx?SID=1970e7dcc6a6fb934d0fb596aad264f9&mc=true&tpl=/ecfrbrowse/Title21/21cfr211_main_02.tpl
- 2.FDA US. Guidance for Industry CGMP for Phase 1 Investigational Drugs. Rockville; 2008.Google Scholar
- 13.Food and Drug Administration. General Labeling Provisions. Code of Federal Regulations Title 21; Apr 1, 2015 pp. 1–17.Google Scholar
- 14.National Institutes of Health. RFA-RM-10-001: Institutional Clinical and Translational Science Award (U54) [Internet]. 2016 [cited 2016 May 11]. pp. 1–40. Available from: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-10-001.html#SectionI